Skip to search formSkip to main contentSkip to account menu

Pegylated Liposomal Irinotecan

A formulation of polyethylene glycol (PEG)-modified liposomes encapsulating the semisynthetic derivative of camptothecin irinotecan, with… 
National Institutes of Health

Related topics

Related topics

9 relations
ApoptosisCYP3A7 protein, humanDNA Replication InhibitionDNA Strand Break

Narrower (1)

IHL-305

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors [Corrigendum]
On page 1208, Disclosure section, “The authors report no conflicts of interest in the work” has been updated since publication… 
Review
2018
Review
2018
Pegylated Liposomal Irinotecan Hydrochloride Trihydrate for Treating Pancreatic Cancer After Gemcitabine: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
The National Institute for Health and Care Excellence (NICE) invited the manufacturer (Shire Pharmaceuticals) of pegylated… 
2016
2016
Phase I and pharmacokinetic (PK) study of IHL-305 (pegylated liposomal irinotecan) in patients with advanced solid tumors.
2547 Background: Irinotecan (CPT-11) is a prodrug of SN-38 that has antitumor activity in a wide range of solid tumors. IHL- 305… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)